Nuvectis Pharma (NVCT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.02
- Estimate
- -$0.24
- Surprise
- -322.1%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Nuvectis Pharma (NVCT) reported a wider loss than forecast — adjusted EPS of -$1.02 against the -$0.24 estimate (a 322.1% shortfall).
Coverage in the report window
- Nuvectis Pharma Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-04
- Nuvectis Pharma Q3 2026 Earnings Call Transcript — benzinga, 2026-11-04
- Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate — benzinga, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVCT Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -322.1% surprise compares with a -80.0% four-quarter average.
What argues against it
- Concentration risk — Pipeline: NXP900
- Concentration risk — Counterparty: University of Edinburgh (NXP900 license)
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.47
- Price target
- $30.80
- Stop
- $17.18
- Upside to target
- +66.8%
- Reward-to-risk
- 4.5:1
Risk check: trading volume is running 2.0× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
NVCT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $602.9M
- P/E (fwd)
- -19.2
- 52-week range
- $5.55–$29.27
- Off 52-week high
- 36.9%
- RSI (14)
- 47
- Volume vs avg
- 2.05×
- Score today
- 5.3/10